Company Shares of Northwest Biotherapeutics (NASDAQ:NWBO) Drops by -11.99%

Northwest Biotherapeutics (NASDAQ:NWBO) : During the past 4 weeks, traders have been relatively bearish on Northwest Biotherapeutics (NASDAQ:NWBO), hence the stock is down -23.05% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -13.1% relative to the S&P 500. The 4-week change in the price of the stock is -21.8% and the stock has fallen -11.99% in the past 1 week.

The company shares have dropped -95.02% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $12.55 and the one year low was seen on Jul 6, 2016. The 50-Day Moving Average price is $0.67 and the 200 Day Moving Average price is recorded at $1.58.

The stock has recorded a 20-day Moving Average of 12.75% and the 50-Day Moving Average is 36.74%.


Northwest Biotherapeutics (NASDAQ:NWBO): stock turned positive on Friday. Though the stock opened at $0.51, the bulls momentum made the stock top out at $0.55 level for the day. The stock recorded a low of $0.5 and closed the trading day at $0.5279, in the green by 5.56%. The total traded volume for the day was 680,388. The stock had closed at $0.5001 in the previous days trading.

In an insider trading activity, Jasinowski Jerry J, director of Northwest Biapeutics Inc, had purchased 79,317 shares on October 18, 2012. The total value of the transaction was $412,448. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. The Companys platform technology, DCVax, uses activated dendritic cells to mobilize a patients own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells. DCVax is designed to target a set of biomarkers on the patients tumor. DCVax product lines are made from the patients own dendritic cells, which are freshly isolated, and matured and activated. The Companys DCVax product lines include DCVax-L, DCVax-Direct and DCVax-Prostate. DCVax-L is made with cancer antigens from tumor lysate. DCVax-Direct incorporates a set of tumor antigens in situ. DCVax-Prostate product line is developed based on the antigen, PSMA (Prostate Specific Membrane Antigen), which is found on all late stage prostate cancers.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.